Shanxi Liuqing Pharmaceutical Co., Ltd Shanxi Liuqing Pharmaceutical Co., Ltd chinese    Shanxi Liuqing Pharmaceutical Co., Ltdenglish
Search
产品检索

Raw material medicine low valued features high quality varieties

Update:2014-7-22 14:49:35   From::本站   Editer:admin   

According to China Chemical Pharmaceutical Industry Association statistics, in 2013, the Chinese chemical pharmaceutical industry's main business income is 955080000000 yuan, grow 13.70% compared to the same period. The raw materials, the main business income 381990000000 yuan,grow 13.7% compared to the same period. At present, irreplaceable status China medicine raw materials in the international market, citric acid, heparin sodium, vitamin, amino acids, antibiotics,paracetamol and other bulk raw material medicine a significant competitive advantage. However, in obtaining scale benefit at the same time, because of the domestic production of the pursuit of low-cost and sacrifice the environment. When the share more and raw material medicine in the international market is small, profit is more and more low, if our country can't be the deep processing of raw materials, then, these raw materials can only be as low value-added common chemical raw material for sale.

Industry experts agree that, raw material medicine domestic enterprises urgently need a new pathfor raw materials and development, adopt differential mode innovation and transformation. To consolidate the undertaking shall as soon as possible upgrade Shen Xianji, deputy director of the Committee of experts Chinese Chemical Pharmaceutical Industry Association said, pharmaceutical raw material industry of our country to strengthen the global industry dominant position, we needto accelerate the pace of transformation and upgrading, based on ensuring the quality of the drug substance to the field of preparation, characteristics of raw material medicine production shift,change the concept of development, steering technology advantage from the price advantage.

Shen Xianji introduces, at present a considerable number of domestic product price advantage is very fragile, Chinese material medicine industry is in a difficult period hitherto unknown, namely"new point of growth is not formed, the comparative advantage of the old is disappearing."

Shen Xianji introduces, at present a considerable number of domestic product price advantage is very fragile, Chinese material medicine industry is in a difficult period hitherto unknown, namely"new point of growth is not formed, the comparative advantage of the old is disappearing."

Therefore, innovation is key, because cannot buy core technology, key technology, only rely on independent innovation. Retrospect of 2013 exports of chemical raw materials of our countrycommodity, the whole is present the quantity or price trend, but also has the minority varietymarket rose.

Retrospect of 2013 exports of chemical raw materials of our country commodity, the whole ispresent the quantity or price trend, but also has the minority variety market rose. For example,antipyretic analgesic category of ethyl amino phenol, hormones cortisone products; in addition, the drug export situation with high technical content of the good performance, such as insulin containing drugs, of three, in preparation of medicines containing artemisinin and its derivatives.Shen Xianji is expected in 2014, Chinese import and export trade will face RMB appreciation, rising labor costs, as well as weak demand in the US and Europe and import regulatory challenges.

Research and development of new drugs to jump Mogao

China Pharmaceutical Industry Research Institute Vice President Yu Xiong said: "2013, global drugR & D investment of 3 companies, Roche investment of $9910000000, Novartis, $9852000000,$8183000000 Johnson." The domestic pharmaceutical industry in developing new drugs and international level gap first in the domestic pharmaceutical R & D investment insufficiency.

"R & D investment needs to be improved." In Yu Xiong's view, the global pharmaceutical innovation and market structure has been changed obviously, which is one of the medicine and the rapid rise of emerging markets and the global pharmaceutical industry chain to accelerate the transfer. They will be China as generics, China pharmaceutical enterprises should make full use of thisopportunity, depth docking leveraging and international innovation resources, promote the Chinaimitation innovation level, this is the new opportunity and the challenge of pharmaceuticalenterprises.

The 2011-2015, annual world drug market growth dropped to about 5%, growth slowed. Is expected in 2016 the world drug market will be close to $12, growth rebound. Yu Xiong suggested,raw material drug can now focus on key projects to support major generic drugs industry of special. For example, the industrialization of varieties to chiral asymmetric synthesis technology as the foundation; biological fermentation, green manufacturing, biotransformation technologyvarieties; the major disease spectrum of drug treatment, including cancer, diabetes,cardiovascular, antiviral drugs in the blockbuster drugs.

It is worth mentioning that the antitumor drug research and development. But Yu Xiong suggested that, from a global perspective, blockbuster products less approved tumor treatment. High quality green raw material medicine opportunity show Health Network General Manager Wu Huifang said:"2013, regardless of the bulk raw material or a common API widespread imbalance of demand and capacity, cost and price does not adapt, and in conflicts around looking for balance: on the one hand, under the pressure of environmental protection and market demand not flourishing, industryupgrading and adjustment, on the other hand, the new production will continue to release; expandto the international market, the digestion of excess capacity, on the other hand to experience more stringent regulatory policy and access threshold." Wu Huifang think, after the process improvement of high-quality green products or will be recast brilliant engine API industry. Wu Huifang think, after the process improvement of high-quality green products or will be recast brilliant engine API industry.

In 2013 China's raw materials import and export growth remained stable, the total import the drugcategories was $19200000000, an increase of 7.87%.

The export side, chemical raw materials and intermediates is still the main.

However, in 2011 to 2013, raw material medicine slowdown, once again into the period of stagnation, the price factor is the main reason leading to total exports grew weak. However, in2011 to 2013, raw material medicine slowdown, once again into the period of stagnation, the price factor is the main reason leading to total exports grew weak. Look on the whole, commodityovercapacity consequences still not subsided, additional amplification products such as vitamin C,penicillin, erythromycin thiocyanate, azithromycin, semi synthesis of raw materials is still the most concentrated industry production overcapacity, the most outstanding products, price of this kind ofraw material medicine in recent years have been running low.

Wu Huifang introduces, carries on the segmentation to the product categories found, immuneserum amino acids, biological products, pharmaceutical and chemical products based and antibiotic raw materials is the main component of imports; antibiotics, vitamins, amino acids,sweeteners, and steroid hormone API is a major component of exports. "From the data point of view, is still the bulk products, low value-added exports accounted for a dominant position."

"From the data point of view, is still the bulk products, low value-added exports accounted for a dominant position." In addition, in 2013 exports drug varieties of billions of dollars 29 A total of 31,than in 2012 reduced 2.

The main reason is the price decline has affected the growth in total. Among them, heparin sodium, citric acid, vitamin E, the 3 largest amount varieties was decreased; threonine, amoxicillin,chondroitin sulfate, choline chloride, meropenem and intermediate varieties are rising. Among them, heparin sodium, citric acid, vitamin E, the 3 largest amount varieties was decreased;threonine, amoxicillin, chondroitin sulfate, choline chloride, meropenem and intermediate varietiesare rising.

Wu Huifang said, in 2014 the new capacity may reduce raw material medicine, but does not mean that the industry will be in smooth water, some products in the driver specific opportunities and benefits will also has new capacity, such as steroid biotransformation of new technologyindustrialization, and market induced intermediates and saponin and downstream products of a new round of increasing signs of expansion. "2014 in the general direction, not reform, pricing andbidding principle of changing the nature, field downstream agents may not have more newincrement opportunity, raw material medicine industry should look to innovation and transformationin the green, sustainable development, rational callback raw material price and reduce excess capacity, it will ease the current industry downturn."


Product Search